Stephen Letrent

Stephen Letrent is a seasoned professional in the biopharmaceutical industry, currently serving as Chief Development Officer at TORL BioTherapeutics, LLC since March 2020, where leadership has facilitated the clinical development of multiple novel cancer therapeutics. Letrent has also contributed to Talus Bio as a member of the Scientific Advisory Board since September 2023 and previously held the role of Head of Development at 1200 Pharma until December 2023. Prior experience includes significant leadership positions at Kyowa Kirin International plc, Pfizer, Bristol-Myers Squibb, and an early career as a Clinical Pharmacist at Thomas Jefferson University Hospitals. Letrent holds a Ph.D. from the University of North Carolina at Chapel Hill, a Pharm.D. from the University of the Sciences in Philadelphia, and a B.S. from Duquesne University.